Sarcomas

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Latest News

2rogan – stock.adobe.com
Elraglusib Earns FDA Rare Pediatric Disease Designation for Ewing Sarcoma

November 12th 2024

The FDA has awarded rare pediatric disease designation to the novel GSK-3β inhibitor elraglusib for the treatment of Ewing sarcoma.

Pimicotinib in Tenosynovial Giant Cell Tumor | Image Credit: © 2rogan - stock.adobe.com
Pimicotinib Meets ORR End Point in Tenosynovial Giant Cell Tumor

November 12th 2024

Fixed-Dose CAR T Cells and UB-TT170 in R/R Osteosarcoma | Image Credit: © MdBabul - stock.adobe.com
Fixed-Dose CAR T Cells Followed by Escalating UB-TT170 Increases Cytokine Levels in R/R Osteosarcoma

November 11th 2024

Here is your snapshot of all therapeutic options that the FDA approved in October 2024.
OncLive’s October Roundup of Key FDA Approvals in Oncology

November 5th 2024

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.
The OncFive: Top Oncology Articles for the Week of 10/27

November 2nd 2024

Latest CME Events & Activities

26th Annual International Lung Cancer Congress®

July 25-26, 2025

Register Now!

PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable ...

November 16, 2024

Register Now!

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease

View More

Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition

December 6, 2024

Register Now!

How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer

View More

Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…

View More

The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape

View More

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

View More

18th Annual New York GU Cancers Congress™

March 28-29, 2025

Register Now!

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

View More

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

View More

BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

<1
...